DudeDiligence.

Zevra Therapeutics, Inc

ZVRANASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$12.0MDec ’24$20.4MMar ’25$25.9MJun ’25$26.1MSep ’25$34.1MDec ’25$36.2MMar ’26$39.7MJun ’26$37.8MSep ’26
Net income, by quarter
−$35.7MDec ’24−$3.1MMar ’25$74.7MJun ’25−$544,000Sep ’25$12.2MDec ’25$37.9MMar ’26$8.8MJun ’26$19.2MSep ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$28.6M$10.2M$27.5M$23.6M$106.5M
Gross profit$26.6M$9.9M$24.5Mnone on filenone on file
Operating income$7.7M−$42.6M−$49.6M−$87.0M−$62.9M
Net income−$8.6M−$26.8M−$46.0M−$105.5M$83.2M
Operating cash flow$10.4M−$18.7M−$33.5M−$69.7M−$1.6M
Free cash flow$10.3M−$18.8M−$33.8M−$69.7M−$2.4M
Cash$112.3M$65.5M$43.0M$33.8M$62.4M
Debtnone on filenone on file$5.1M$59.5M$61.9M
Shares outstanding35.0M34.5M41.5M53.7M56.9M